PMID- 35844573
OWN - NLM
STAT- MEDLINE
DCOM- 20220719
LR  - 20220719
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Immunological Changes of Basophil Hyperreactivity to Sweat in Patients With 
      Well-Controlled Atopic Dermatitis.
PG  - 883605
LID - 10.3389/fimmu.2022.883605 [doi]
LID - 883605
AB  - BACKGROUND: Sweat aggravates atopic dermatitis (AD). In patients with AD, type-I 
      hypersensitivity to sweat may be shown by histamine release from patients' 
      basophils in response to the semi-purified sweat antigen (QR), and the presence 
      of specific immunoglobulin E (IgE) binding to MGL_1304, the component of QR. 
      However, there has been no information on the immunological changes of type-I 
      hypersensitivity to the sweat antigen in patients with well-controlled AD using 
      topical corticosteroids (TCSs) and/or biologics as treatments. METHOD: 
      Histamine-releasing tests using patients' basophils and QR and the detection of 
      serum IgE against MGL_1304 and mite allergen Der f 1 were performed in patients 
      with AD who were well controlled by topical TCS with/without dupilumab for 53-96 
      weeks. RESULTS: In total, 14 patients were enrolled. Seven patients received TCS 
      therapy alone (TCS group), and seven patients received TCS with dupilumab therapy 
      (dupilumab group). In all participants, the level of specific IgE against 
      MGL_1304 decreased after treatments, but histamine release from basophils in 
      response to QR did not show a statistically significant reduction; rather, it 
      increased. In the dupilumab group, all changes in histamine release induced by QR 
      (increase), the IgE level against MGL_1304 (decrease), and that against Der f 1 
      (decrease) were statistically significant, whereas the TCS group showed no 
      significant change in any of them. CONCLUSION: The well-controlled condition for 
      53-96 weeks resulted in no reduction of the hyperreactivity of basophils against 
      in patients with AD, even with the treatment with dupilumab. This study suggests 
      persistent basophil hyperreactivity to sweat antigen over a year or longer.
CI  - Copyright (c) 2022 Numata, Takahagi, Ishii, Morioke, Kan, Mizuno, Yanase, 
      Kawaguchi, Tanaka and Hide.
FAU - Numata, Tomofumi
AU  - Numata T
AD  - Department of Dermatology, Graduate School of Biomedical & Health Sciences, 
      Hiroshima University, Hiroshima, Japan.
FAU - Takahagi, Shunsuke
AU  - Takahagi S
AD  - Department of Dermatology, Graduate School of Biomedical & Health Sciences, 
      Hiroshima University, Hiroshima, Japan.
FAU - Ishii, Kaori
AU  - Ishii K
AD  - Department of Dermatology, Graduate School of Biomedical & Health Sciences, 
      Hiroshima University, Hiroshima, Japan.
FAU - Morioke, Satoshi
AU  - Morioke S
AD  - Department of Dermatology, Graduate School of Biomedical & Health Sciences, 
      Hiroshima University, Hiroshima, Japan.
FAU - Kan, Takanobu
AU  - Kan T
AD  - Department of Dermatology, Graduate School of Biomedical & Health Sciences, 
      Hiroshima University, Hiroshima, Japan.
FAU - Mizuno, Hayato
AU  - Mizuno H
AD  - Department of Dermatology, Graduate School of Biomedical & Health Sciences, 
      Hiroshima University, Hiroshima, Japan.
FAU - Yanase, Yuhki
AU  - Yanase Y
AD  - Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, 
      Hiroshima University, Hiroshima, Japan.
FAU - Kawaguchi, Tomoko
AU  - Kawaguchi T
AD  - Department of Dermatology, Graduate School of Biomedical & Health Sciences, 
      Hiroshima University, Hiroshima, Japan.
FAU - Tanaka, Akio
AU  - Tanaka A
AD  - Department of Dermatology, Graduate School of Biomedical & Health Sciences, 
      Hiroshima University, Hiroshima, Japan.
FAU - Hide, Michihiro
AU  - Hide M
AD  - Department of Dermatology, Graduate School of Biomedical & Health Sciences, 
      Hiroshima University, Hiroshima, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220629
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antigens)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Antigens
MH  - *Basophils
MH  - *Dermatitis, Atopic
MH  - Histamine Release
MH  - Humans
MH  - Immunoglobulin E
MH  - Sweat/metabolism
PMC - PMC9277351
OTO - NOTNLM
OT  - IgE
OT  - MGL_1304
OT  - Malassezia
OT  - atopic dermatitis
OT  - basophil
OT  - dupilumab
OT  - histamine release
OT  - sweat antigen
COIS- TN has received a research grant from Sun pharma and Kyowa-Kirin. ST has received 
      a research grant from Sanofi, Maruho, and Taiho Pharma and an honorarium from 
      Novartis. MH has received a research grant from GlaxoSmithKline, Kaken 
      Pharmaceutical, Mitsubishi-Tanabe, Novartis, Sanofi, and Taiho Pharma, honorarium 
      from Ely-Lilly, Kaken-Pharmaceutical, Kyowa-Kirin, Mitsubishi-Tanabe, MSD, 
      Novartis, Sanofi, Taiho Pharma, Teikoku seiyaku, and Uriach. AT has received a 
      research grant from Maruho, Sanofi, Eisai, and Mitsubishi Tanabe Pharma and an 
      honorarium from Maruho, Torii Pharma, Mitsubishi Tanabe Pharma, Sanofi, and Taiho 
      Pharma. The remaining authors declare that the research was conducted in the 
      absence of any commercial or financial relationships that could be construed as a 
      potential conflict of interest.
EDAT- 2022/07/19 06:00
MHDA- 2022/07/20 06:00
PMCR- 2022/01/01
CRDT- 2022/07/18 03:39
PHST- 2022/02/25 00:00 [received]
PHST- 2022/05/23 00:00 [accepted]
PHST- 2022/07/18 03:39 [entrez]
PHST- 2022/07/19 06:00 [pubmed]
PHST- 2022/07/20 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.883605 [doi]
PST - epublish
SO  - Front Immunol. 2022 Jun 29;13:883605. doi: 10.3389/fimmu.2022.883605. eCollection 
      2022.